This study was conducted in the context of a doctoral thesis (C. E.).
A retrospective analysis of radiation therapy for the treatment of feline vaccine-associated sarcoma*
Article first published online: 12 FEB 2009
© 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Ltd
Veterinary and Comparative Oncology
Volume 7, Issue 1, pages 54–68, March 2009
How to Cite
Eckstein, C., Guscetti, F., Roos, M., Martín de las Mulas, J., Kaser-Hotz, B. and Rohrer Bley, C. (2009), A retrospective analysis of radiation therapy for the treatment of feline vaccine-associated sarcoma. Veterinary and Comparative Oncology, 7: 54–68. doi: 10.1111/j.1476-5829.2008.00173.x
- Issue published online: 12 FEB 2009
- Article first published online: 12 FEB 2009
- coarse fractionated radiotherapy;
- curative radiotherapy;
- feline vaccine-associated sarcoma;
- Ki67 index
We retrospectively evaluated predictive prognostic factors in 73 cats with vaccine-associated sarcoma given postsurgical curative (n = 46, most with clean margins) or coarse fractionated radiotherapy (n = 27, most with either macroscopic disease or dirty margins). The former animals displayed a median survival of 43 months and a median progression free interval (PFI) of 37 months, the latter reached a median survival of 24 months and a median PFI of 10 months. In cats undergoing coarse fractionated therapy, factors predictive of a better outcome included lack of visible mass (n = 10) as opposed to macroscopic disease (n = 17, survival: 30 versus 7 months, P = 0.025; PFI: 20 versus 4 months, P = 0.01), adjuvant chemotherapy for gross disease (n = 5/17, survival: 29 versus 5 months, P = 0.04) and a smaller number of surgeries preceding radiation therapy (coeff = 0.41, P = 0.03). The Ki67 index was not predictive for survival. We concluded that postsurgical curative and coarse fractionated radiotherapy are effective legitimate options for managing vaccine-associated sarcomas.